Physician profile
Robert Dray
NPI 1598792343
$4,723.03
in general payments reported to CMS, 2019-2025
31 companies · $24.95 in 2025
The $24.95 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $685 · 2020: $407 · 2021: $917 · 2022: $1,202 · 2023: $1,096 · 2024: $392 · 2025: $24.95.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,512.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,512.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $794.47 | 2019-2023 | Myrbetriq, Veozah |
| Abbvie INC. | $626.71 | 2019-2024 | Lupron Depot, Botox |
| Rochester Medical Corporation | $390.34 | 2019-2022 | |
| Boston Scientific Corporation | $381.26 | 2019-2023 | Advantage System, Rezum Generator, Solyx Sis System |
| Procept Biorobotics Corporation | $262.44 | 2022 | |
| Janssen Biotech, INC. | $242.82 | 2019-2024 | Erleada, Akeega, Balversa |
| Urovant Sciences INC | $229.02 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $205.29 | 2023-2025 | Gemtesa |
| Coloplast Corp | $171.79 | 2020-2024 | Speedicath |
| Urogen Pharma, INC. | $136.45 | 2021-2023 | Jelmyto |
| C. R. Bard, INC. & Subsidiaries | $129.18 | 2019-2024 | Bard Urinary Drainage Bag |
| Myovant Sciences INC. | $127.52 | 2021-2022 | |
| Intuitive Surgical, INC. | $83.82 | 2023 | Da Vinci Surgical System |
| Medtronic, INC. | $82.52 | 2021-2024 | Interstim |
| Endo Pharmaceuticals INC. | $80.84 | 2019-2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $80.35 | 2022 | |
| Olympus America INC. | $78.02 | 2019-2023 | Itind System |
| Bayer Healthcare Pharmaceuticals INC. | $73.00 | 2021-2023 | |
| Axonics, INC. | $72.53 | 2021-2022 | |
| Stryker Corporation | $71.83 | 2022 | |
| Clarus Therapeutics INC. | $64.03 | 2021 | |
| Dendreon Pharmaceuticals LLC | $43.97 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $42.46 | 2022-2023 | Seglentis |
| Accord Healthcare, INC. | $42.39 | 2024 | |
| Ferring Pharmaceuticals INC. | $42.35 | 2019 | |
| Pfizer INC. | $39.09 | 2019 | |
| Laborie Medical Technologies Corp. | $38.92 | 2020-2021 | |
| Mission Pharmacal Company | $30.21 | 2019-2024 | Uribel Tabs |
| Tolmar, INC. | $21.85 | 2024 | |
| Travere Therapeutics, INC. | $20.52 | 2019 | |
| 180 Medical, INC. | $17.04 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Dray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.